PubRank

Radek C Skoda

Author PubWeight™ 73.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005 21.48
2 Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2007 3.52
3 Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood 2006 2.88
4 Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med 2007 2.85
5 Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006 2.74
6 Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014 2.72
7 Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010 2.61
8 Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007 2.44
9 Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood 2011 2.27
10 The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011 2.20
11 JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008 2.05
12 The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006 1.89
13 A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica 2008 1.63
14 Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011 1.56
15 The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica 2008 1.45
16 Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 2008 1.39
17 Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003 1.35
18 Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2008 1.33
19 Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005 1.31
20 Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008 1.27
21 Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 2008 1.23
22 Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood 2012 1.07
23 Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica 2009 0.99
24 Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells. Blood 2004 0.97
25 Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 2005 0.94
26 SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood 2011 0.92
27 Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica 2014 0.87
28 Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood 2014 0.86
29 The DEAH-box helicase RHAU is an essential gene and critical for mouse hematopoiesis. Blood 2012 0.86
30 Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood 2010 0.83
31 Normal erythropoiesis but severe polyposis and bleeding anemia in Smad4-deficient mice. Blood 2007 0.82
32 A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J Biol Chem 2004 0.80
33 A 2-kb c-mpl promoter fragment is sufficient to direct expression to the megakaryocytic lineage and sites of embryonic hematopoiesis in transgenic mice. Blood 2002 0.80
34 Raising hematology's European voice: the importance of calling yourself a hematologist. Haematologica 2012 0.79
35 Hereditary myeloproliferative disorders. Haematologica 2010 0.77
36 Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood 2011 0.75
37 Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost 2014 0.75
38 Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood 2013 0.75